Pramipexole enhances reward learning by preserving value estimates by Halahakoon, DC, Kaltenboeck, A, Martens, M, Geddes, JG, Harmer, CJ, Cowen, P, Browning, M

“…This is a plausible mechanism for pramipexole’s antidepressant effect.</p>…”

Effects of pramipexole on the processing of rewarding and aversive taste stimuli by McCabe, C, Harwood, J, Brouwer, S, Harmer, C, Cowen, P

“…Rationale: Pramipexole, a D2/D3 dopamine receptor agonist, has been implicated in the development of impulse control disorders in patients with Parkinson's disease. …”

Effects of pramipexole on the processing of rewarding and aversive taste stimuli. by Mccabe, C, Harwood, J, Brouwer, S, Harmer, C, Cowen, P

“…RATIONALE: Pramipexole, a D2/D3 dopamine receptor agonist, has been implicated in the development of impulse control disorders in patients with Parkinson's disease. …”

Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis by Tundo, A, De Filippis, R, De Crescenzo, F

“…Our aim was to systematically review the effectiveness and safety of pramipexole in unipolar and bipolar depression. <br/><br/> <strong>Methods</strong> We conducted a systematic review of randomized clinical trials (RCTs) and observational studies on pramipexole for patients with major depressive episodes, following PRISMA guidelines. …”

Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release by Pes, R, Godar, S, Fox, A, Burgeno, L, Strathman, H, Jarmolowicz, D, Devoto, P, Levant, B, Phillips, P, Fowler, S, Bortolato, M

“…Pramipexole (PPX) is a high-affinity D2-like dopamine receptor agonist, used in the treatment of Parkinson's disease (PD) and restless leg syndrome. …”

An experimental medicine investigation of the effects of subacute pramipexole treatment on emotional information processing in healthy volunteers by Martens, MAG, Kaltenboeck, A, Halahakoon, DC, Browning, M, Cowen, PJ, Harmer, CJ

“…Treatment with the dopamine D2/D3 receptor agonist pramipexole has demonstrated promising clinical effects in patients with depression. …”

The effects of pramipexole on motivational vigour during a saccade task: a placebo-controlled study in healthy adults by Au-Yeung, SK, Halahakoon, DC, Kaltenboeck, A, Cowen, P, Browning, M, Manohar, SG

“…Healthy adult participants were randomised to receive either pramipexole (n = 19) or placebo (controls n = 18) for 18 days. …”

Enhanced taste recognition following subacute treatment with the dopamine D2/D3 receptor agonist pramipexole in healthy volunteers by Kaltenboeck, A, Halahakoon, DC, Harmer, C, Cowen, P, Browning, M

“…<br> <strong>Results:</strong> Compared to the placebo group, participants receiving pramipexole showed significantly higher total recognition accuracy (Median Pramipexole = 14.0, Median Placebo = 13.0, U = 264.5, p = 0.04). …”

PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression by Au-Yeung, S, Griffiths, J, Roberts, S, Edwards, C, Bogacz, R, Attenburrow, M-J, Watson, S, Cleare, A, Harmer, C, Kessler, D, Yu, L-M, Chan, F, Cipriani, A, Rendell, J, Evans, J, Lewis, G, Singh, I, Simon, J, Harrison, P, Cowen, P, Shanyinde, M, Geddes, J, Browning, M

“…PAX-D will compare the effects of pramipexole versus placebo when added to current antidepressant medication for people with TRD. …”

Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study) by Azim, L, Hindmarch, P, Browne, G, Chadwick, T, Clare, E, Courtney, P, Dixon, L, Duffelen, N, Fouweather, T, Geddes, JR, Goudie, N, Harvey, S, Helter, T, Holstein, E-M, Martin, G, Mawson, P, McCaffery, J, Morriss, R, Simon, J, Smith, D, Stokes, PRA, Walker, J, Weetman, C, Wolstenhulme, F, Young, AH, Watson, S, McAllister-Williams, RH

“…This demonstrates an unmet need for additional interventions. Pramipexole has been shown to improve mood symptoms in animal models of depression, in people with Parkinson’s Disease and two proof of principle trials of pramipexole for people with BD who are currently depressed.…”

Serotonin and dopamine play complementary roles in gambling to recover losses. by Campbell-Meiklejohn, D, Wakeley, J, Herbert, V, Cook, J, Scollo, P, Ray, M, Selvaraj, S, Passingham, R, Cowen, P, Rogers, R

“…In Experiment 2, participants received a single 176 μg dose of the D(2)/D(3) receptor agonist, pramipexole, or placebo. In Experiment 3, participants received a single 80 mg dose of the beta-adrenoceptor blocker, propranolol, or placebo. …”

Backing into the future: pharmacological approaches to the management of resistant depression by Cowen, P

“…Finally an older drug, the dopamine receptor agonist pramipexole, if used carefully may well improve the prospects of depressed patients who are refractory to current approaches. …”

Are all antidepressants really the same? The case of fluoxetine: a systematic review. by Cipriani, A, Barbui, C, Brambilla, P, Furukawa, T, Hotopf, M, Geddes, J

“…In terms of tolerability, patients allocated to fluoxetine were less likely to leave the study early only in comparison with those allocated to amitriptyline and pramipexole. CONCLUSIONS: This systematic review highlighted that there are differences between fluoxetine and specific comparator antidepressants. …”

Fluoxetine versus other types of pharmacotherapy for depression by Cipriani, A, Brambilla, P, Furukawa, T, Geddes, J, Gregis, M, Hotopf, M, Malvini, L, Barbui, C

“…Fluoxetine was better tolerated than TCAs considered as a group (Peto OR: 0.78, 95% CI 0.68 to 0.89), and was better tolerated in comparison with individual ADs, in particular than amitriptyline (Peto OR: 0.64, 95% CI 0.47 to 0.85) and imipramine (Peto OR: 0.79, 95% CI 0.63 to 0.99), and among newer ADs than ABT-200 (Peto OR: 0.21, 95% CI 0.10 to 0.41), pramipexole (Peto OR: 0.20, 95% CI 0.08 to 0.47) and reboxetine (Peto OR: 0.61, 95% CI 0.40 to 0.94). …”

Fluoxetine versus other types of pharmacotherapy for depression. by Cipriani, A, Brambilla, P, Furukawa, T, Geddes, J, Gregis, M, Hotopf, M, Malvini, L, Barbui, C

“…Fluoxetine was better tolerated than TCAs considered as a group (PetoOR: 0.78, 95% CI 0.68 to 0.89), and was better tolerated in comparison with individual ADs, in particular than amitriptyline (PetoOR: 0.64, 95% CI 0.47 to 0.85) and imipramine (PetoOR: 0.79, 95% CI 0.63 to 0.99), and among newer ADs than ABT-200 (PetoOR: 0.21, 95% CI 0.10 to 0.41), pramipexole (PetoOR: 0.20, 95% CI 0.08 to 0.47) and reboxetine (PetoOR: 0.61, 95% CI 0.40 to 0.94). …”